Cliftonlarsonallen Wealth Advisors LLC Cuts Stock Holdings in Pfizer Inc. (NYSE:PFE)

Cliftonlarsonallen Wealth Advisors LLC decreased its holdings in Pfizer Inc. (NYSE:PFE) by 3.3% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 17,486 shares of the biopharmaceutical company’s stock after selling 604 shares during the period. Cliftonlarsonallen Wealth Advisors LLC’s holdings in Pfizer were worth $506,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. Olistico Wealth LLC acquired a new position in shares of Pfizer during the second quarter worth $25,000. MFA Wealth Advisors LLC acquired a new position in shares of Pfizer during the second quarter valued at about $29,000. Quarry LP acquired a new stake in Pfizer in the 2nd quarter worth approximately $31,000. Creekmur Asset Management LLC acquired a new stake in shares of Pfizer during the fourth quarter worth $32,000. Finally, Trivant Custom Portfolio Group LLC lifted its position in Pfizer by 100.0% during the 1st quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 600 shares during the period. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Up 1.3 %

Shares of PFE opened at $29.46 on Wednesday. The stock has a 50 day moving average price of $29.02 and a 200 day moving average price of $28.41. Pfizer Inc. has a one year low of $25.20 and a one year high of $33.92. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.60 and a current ratio of 0.86. The stock has a market capitalization of $166.94 billion, a price-to-earnings ratio of -491.00, a PEG ratio of 1.30 and a beta of 0.67.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.46 by $0.14. The business had revenue of $13.28 billion during the quarter, compared to analyst estimates of $12.96 billion. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The company’s revenue for the quarter was up 2.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.67 earnings per share. Equities research analysts forecast that Pfizer Inc. will post 2.66 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be issued a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a dividend yield of 5.70%. The ex-dividend date of this dividend is Friday, November 8th. Pfizer’s dividend payout ratio is currently -2,800.00%.

Analyst Ratings Changes

PFE has been the subject of a number of research reports. Daiwa America raised Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Wells Fargo & Company increased their price target on Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 31st. Daiwa Capital Markets raised Pfizer from a “neutral” rating to an “outperform” rating and boosted their price objective for the company from $28.00 to $34.00 in a report on Wednesday, August 7th. Barclays raised their target price on Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. Finally, UBS Group raised their price objective on shares of Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 31st. Eight equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $34.54.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.